HIV Gag peptide SLYNTVATL (HLA-A*0201)

IBA Lifescience Kontakt z doradcą
Single peptide synthesized as presented by the MHC class I allele
HIV Gag peptide SLYNTVATL (HLA-A*0201)

HIV Gag peptide SLYNTVATL (HLA-A*0201) is a single peptide for stimulation of T cells. The peptide from human immunodeficiency virus (HIV) group-specific antigen (Gag) is synthesized as it is presented by the MHC class I HLA-A*0201 allele and can be used for targeted in vitro generation and expansion of antigen-specific CD8+ T cells. The peptides were purified by HPLC using a water and acetonitrile gradient and are endotoxin-free.

Specifications

  • Form: Lyophilized powder
  • Peptide Sequence: SLYNTVATL
  • Possible Application: T cell stimulation
  • Purity: > 85%
  • Sterility: Sterile
  • MHC I Compatibility: HLA-A*0201

Podobne produkty

CD19 Fab-TACS® Agarose Column Starter Kit, human

CD19 Fab-TACS® Agarose Column Starter Kit, human

IBA Lifescience
Więcej
MHC I-Strep HLA-A*0201; UTA2-1 (QLLNSVLTL)

MHC I-Strep HLA-A*0201; UTA2-1 (QLLNSVLTL)

IBA Lifescience
Więcej
Strep-Tactin® PE or APC

Strep-Tactin® PE or APC

IBA Lifescience
Więcej